FierceBiotech 2. Juni 2026 ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
FierceBiotech 2. Juni 2026 ASCO: Celcuity dares to dream of becoming $10B company after breast cancer win over Piqray
FierceBiotech 2. Juni 2026 MindMaze Therapeutics culls program, ends legacy ops from Relief merger to cut costs
FierceBiotech 2. Juni 2026 Abivax stock suffers as cancer cases overshadow stellar efficacy in ulcerative colitis phase 3 trial
FierceBiotech 2. Juni 2026 ASCO: Takeda touts ‘tremendous potential’ of Innovent’s PD-1/IL-2 bispecific after seeing survival data
FierceBiotech 1. Juni 2026 ASCO: Telix tees up pivotal test for Pluvicto challenger while eyeing ‘white space’ on radiopharma canvas
FierceBiotech 1. Juni 2026 Rallybio swerves past Candid pothole to land deal with cancer drug developer Avenzo
FierceBiotech 1. Juni 2026 Agios signs $165M deal for blood disorder drug from Korea’s Oscotec that flunked phase 2 study
FierceBiotech 1. Juni 2026 Servier inks $2.6B buyout of Edgewise’s muscular dystrophy unit to beef up neurology pipeline
FierceBiotech 1. Juni 2026 Lilly locks in 5-program R&D pact with China’s Haisco worth up to $3B, but targets unclear
FierceBiotech 1. Juni 2026 Lilly pens $1.2B deal for Hanmi’s GLP-2 drug being aimed at short bowel syndrome
FierceBiotech 31. Mai 2026 ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout
FierceBiotech 31. Mai 2026 ASCO: Revolution Medicines confident in RAS leadership as rivals square up